“InThera’s E.coli - based VLP manufacturing technology can be applied to abroad range of novel vaccine development. Our diverse pipeline includes unmet-need human vaccines and improved veterinary vaccines. ”

01Strength & Competitiveness of InThera’s next-generation VLP Vaccine

Target Vaccine		Market Strategy	Market Size (at peak sales)
Human unmet vaccine	Norovirus	Novel unmet vaccine	600 Million USD
Human unmet vaccine	Hand, Foot and Mouth Disease(HFMD) Virus	Improved efficacy and safety profile over inactivated vaccine	~ 889 Million USD